The Use of Glycomacropeptide in Dietary Management of Phenylketonuria

Table 2

Levels of follow-up laboratory parameters in all phases.

		Number of samples	Mean	Std. deviation	Min.	Max.		Sig.
S_urea	Baseline								10	20.6	7.66	6	30	.353	0.7
	Phase I	8	17.63	5.18	8	23
	Phase II	6	19.67	9.75	10	37
	Total	24	19.37	7.32	6	37
S_creat	Baseline	10	.44	.15	.2	.7	.44	0.6
	Phase I	9	.38	.13	.2	.6
	Phase II	3	.37	.12	.3	.5
	Total	22	.41	.14	.2	.7
S_Albumin	Baseline	9	4.6	.35	4.2	5.2	.224	0.8
	Phase I	8	4.5	.52	4	5.3
	Phase II	5	4.52	.31	4	4.8
	Total	22	4.5	.40	4	5.3
S_ALT	Baseline	10	15.6	6.18	9	25
	Phase I	9	16.6	4.38	11	26	.09	0.9
	Phase II	5	15.8	5.44	11	25
	Total	24	16	5.2	9	26
S_AST	Baseline	10	23	9.8	7.	37	.49	0.6
	Phase I	9	26	5.6	15	32
	Phase II	5	26.4	4.6	20	31
	Total	24	24.8	7.4	7	37
S_Hb	Baseline	8	11.9	1.51	10.2	14.1	.63	0.5
	Phase I	10	11.49	1.5	10.1	14.7
	Phase II	5	12.38	1.32	10.7	14.1
	Total	23	11.84	1.45	10.1	14.7